Intra-Cellular Therapies Inc (NASDAQ: ITCI) is 51.93% higher on its value in year-to-date trading and has touched a low of $62.78 and a high of $128.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ITCI stock was last observed hovering at around $127.19 in the last trading session, with the day’s loss setting it -0.3%.
Currently trading at $126.89, the stock is 42.49% and 45.32% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 16.59 million and changing -0.24% at the moment leaves the stock 66.17% off its SMA200. ITCI registered 86.58% gain for a year compared to 6-month gain of 61.25%. The firm has a 50-day simple moving average (SMA 50) of $86.4874 and a 200-day simple moving average (SMA200) of $76.0754.
The stock witnessed a 51.28% loss in the last 1 month and extending the period to 3 months gives it a 67.49%, and is 55.16% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.22% over the week and 3.12% over the month.
Intra-Cellular Therapies Inc (ITCI) has around 610 employees, a market worth around $13.45B and $613.73M in sales. Fwd P/E is 343.92. Profit margin for the company is -14.07%. Distance from 52-week low is 102.12% and -0.87% from its 52-week high. The company has generated returns on investments over the last 12 months (-7.46%).
with sales reaching $193.96M over the same period.The EPS is expected to grow by 57.40% this year, but quarterly earnings will post 45.49% year-over-year. Quarterly sales are estimated to grow 46.83% in year-over-year returns.
Intra-Cellular Therapies Inc (ITCI) Top Institutional Holders
489.0 institutions hold shares in Intra-Cellular Therapies Inc (ITCI), with institutional investors hold 98.42% of the company’s shares. The shares outstanding are 106.00M, and float is at 99.09M with Short Float at 2.00%. Institutions hold 96.13% of the Float.
The top institutional shareholder in the company is FMR LLC with over 11.24 million shares valued at $769.68 million. The investor’s holdings represent 11.6003% of the ITCI Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 9.61 million shares valued at $657.98 million to account for 9.9168 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 6.32 million shares representing 6.5255% and valued at over $432.97 million, while WASATCH ADVISORS LP holds 3.8382 of the shares totaling 3.72 million with a market value of $254.66 million.
Intra-Cellular Therapies Inc (ITCI) Insider Activity
The most recent transaction is an insider sale by Mates Sharon, the company’s Chairman and CEO. SEC filings show that Mates Sharon sold 51,000 shares of the company’s common stock on Dec 04 ’24 at a price of $85.80 per share for a total of $4.38 million. Following the sale, the insider now owns 1.07 million shares.
Intra-Cellular Therapies Inc disclosed in a document filed with the SEC on Dec 05 ’24 that Mates Sharon (Chairman and CEO) sold a total of 51,697 shares of the company’s common stock. The trade occurred on Dec 05 ’24 and was made at $84.08 per share for $4.35 million. Following the transaction, the insider now directly holds 1.07 million shares of the ITCI stock.
Still, SEC filings show that on Dec 05 ’24, Mates Sharon (Officer) Proposed Sale 51,697 shares at an average price of $84.02 for $4.34 million. The insider now directly holds shares of Intra-Cellular Therapies Inc (ITCI).
